Anest. intenziv. Med. 2022;33(1):7-13 | DOI: 10.36290/aim.2022.006

Clinical practise of administration of systemic corticosteroids among critically ill patients with COVID-19 in the Czech Republic: survey (ASAP­‑C)Original Article

Maláska J.^{1, 2}, Keller F.¹, Chlebek D.⁸, Stašek J.¹, Hudec J.^{1, 2}, Prokopová T.^{1, 2}, Kratochvíl M.³, Duška F.⁴, Máca J.⁵, Brat K.⁶, Štěpánová R.⁷, Svobodník A.⁷, Klučka J.^{2, 3}, Štourač P.^{2, 3}

¹ Klinika anesteziologie, resuscitace a intenzivní medicíny, Fakultní nemocnice Brno a Lékařská fakulta Masarykovy univerzity Brno

² Ústav simulační medicíny, Lékařská fakulta Masarykovy univerzity Brno

³ Klinika dětské anesteziologie a resuscitace, Fakultní nemocnice Brno a Lékařská fakulta Masarykovy univerzity Brno

⁴ Klinika anesteziologie a resuscitace Fakultní nemocnice Královské Vinohrady a 3. Lékařská fakulta Karlova Univerzita, Praha

⁵ Klinika anesteziologie a resuscitace, Fakultní nemocnice Ostrava a Lékařská fakulta Ostravské Univerzity

⁶ Klinika nemocí plicních a tuberkulózy, Fakultní nemocnice Brno a Lékařská fakulta Masarykovy univerzity Brno

⁷ Farmakologický ústav, Lékařská fakulta Masarykovy univerzity Brno

⁸ Lékařská fakulta Masarykovy univerzity Brno

Study objective: Administration of systemic corticosteroids in patients with severe COVID-19 (Coronavirus Disease 2019) has been recommended by World Health Organization (WHO) according to the RECOVERY trial results. However, there is still ongoing debate regarding the evidence supporting the dose, timing, route of administration and type of corticosteroid. This survey aimed to describe the current clinical practice of administration of systemic corticosteroids for patients with COVID-19 within Intensive Care Units (ICU) in Czech Republic.

Study design: cross-sectional survey



Material and methods: Electronic survey containing 15 questions was sent to the members of Czech Society of Anaesthesiology, Resuscitation and Intensive Care, Czech Society of Intensive care and Czech Pneumological and Phthisiological Society members. The results were analysed by descriptive statistic methods.

Results: The survey fulfilled 233 respondents and 231 answers were eligible for analysis. The most prevalent group was attending physician with completed training in anaesthesiology and intensive care medicine (AIM) (32 %, n = 74). The most prevalent indication for initiation of corticosteroid treatment was oxygen therapy (face mask or nasal cannula) (59,3 %, n = 137) and high-flow nasal oxygen therapy (HFNC) (21,6 %, n = 50). The most preferred corticosteroid was dexamethasone (75,8 %, n = 175) at dose of 8 mg intravenously (i. v.) (48,6 %, n = 85), or dose of 6 mg i. v. (32,0 %, n = 56) followed by methylprednisolone (25,5 %, n= 59) at dose of 80 mg i. v. (35,6 %, n = 21), and 40 mg i. v. (13,6 %, n = 8), respectively. The preferred duration of therapy was 10 days (dexamethasone 60,6 %, n = 106, methylprednisolone 20,3 %, n = 12).

Conclusion: Administration of corticosteroid was dominantly initiated in patients with severe COVID-19 receiving supplemental oxygen. The corticosteroid of first choice was intravenous dexamethasone at dose of 8 mg and 6 mg for 10 days, respectively.

Keywords: COVID-19, ARDS, corticosteroids, critical care, survey.

Received: December 23, 2021; Revised: February 9, 2022; Accepted: February 21, 2022; Published: February 25, 2022  Show citation